Pandemic has caused perfect storm for medtech

Sector is attractive but risky

clock • 4 min read

The Covid-19 pandemic has, together with the rapid rise of medical technology and boom in M&A over the past couple of years, created something of a perfect storm for investment abuses in the medtech sector.

The pandemic itself has created an acute need for complex products with demanding levels of precision on a scale previously unknown - from antigen tests to monitoring equipment such as pulse oximeters, to contact-tracing apps and even ambitious spatial detection devices. Demand is considerable in both the consumer and B2B markets. If the pandemic pushed many consumers to take a greater interest in their health, the buoyant state of medical technology itself was well positioned to receive them. Wearables such as smartwatches and fitness trackers with increasingly sophisticated health mark...

To continue reading this article...

Join Investment Week for free

  • Unlimited access to real-time news, analysis and opinion from the investment industry, including the Sustainable Hub covering fund news from the ESG space
  • Get ahead of regulatory and technological changes affecting fund management
  • Important and breaking news stories selected by the editors delivered straight to your inbox each day
  • Weekly members-only newsletter with exclusive opinion pieces from leading industry experts
  • Be the first to hear about our extensive events schedule and awards programmes

Join now

 

Already an Investment Week
member?

Login

More on Specialist

Deep Dive: Thematics offer diversification but investors must consider bond sensitivity

Deep Dive: Thematics offer diversification but investors must consider bond sensitivity

‘Dedicated specialists’

James Baxter-Derrington
clock 06 April 2023 • 4 min read
European private equity yet to spend €270bn worth of capital

European private equity yet to spend €270bn worth of capital

Deployment of capital expected

Kathleen Gallagher
clock 04 January 2023 • 1 min read
Early-stage biopharma: An opportunity for strategic investment

Early-stage biopharma: An opportunity for strategic investment

Disproportionately smaller investment

Ali H. Munawar
clock 10 August 2022 • 4 min read
Trustpilot